» Articles » PMID: 16682671

MRI T2 Lesion Burden in Multiple Sclerosis: a Plateauing Relationship with Clinical Disability

Overview
Journal Neurology
Specialty Neurology
Date 2006 May 10
PMID 16682671
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Previous studies have shown only modest correlation between multiple sclerosis (MS) lesions on MRI and clinical disability.

Objective: To investigate the relationship between proton density/T2-weighted (T2) burden of disease (BOD) quantitatively measured on MRI scans and clinical determinants including disability.

Methods: Using the Sylvia Lawry Centre for Multiple Sclerosis Research (SLCMSR) database, the authors studied baseline T2 BOD data from a pooled subsample of 1,312 placebo MS patients from 11 randomized controlled trials. Univariate comparisons guided development of multiple regression models incorporating the most important clinical predictors.

Results: Significant, although weak to moderate, correlations were found between T2 BOD and age at disease onset, disease duration, disease course, disability (as measured by the Expanded Disability Status Scale [EDSS]), relapse rate, certain presenting symptoms, and gadolinium enhancement. An unexpected but key finding that persisted in the multiple regression analyses was a plateauing relationship between T2 BOD and disability for EDSS values above 4.5.

Conclusions: This study confirmed the limited correlation between clinical manifestations and T2 burden of disease (BOD) but revealed an important plateauing relationship between T2 BOD and disability.

Citing Articles

Automated Quantitative Susceptibility and Morphometry MR Study: Feasibility and Interrelation Between Clinical Score, Lesion Load, Deep Grey Matter and Normal-Appearing White Matter in Multiple Sclerosis.

Manasseh G, Hilbert T, Fartaria M, Deverdun J, Cuadra M, Marechal B Diagnostics (Basel). 2024; 14(23).

PMID: 39682577 PMC: 11639802. DOI: 10.3390/diagnostics14232669.


Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.

Zivadinov R, Keenan A, Le H, Ait-Tihyaty M, Gandhi K, Zierhut M BMC Neurol. 2024; 24(1):378.

PMID: 39379875 PMC: 11460132. DOI: 10.1186/s12883-024-03888-6.


Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-Results from the MAGNON project.

Leussink V, Jankovic M, Groth M, Schuh K, Schwab Sauerbeck I, Hoffmann O Brain Behav. 2024; 14(6):e3548.

PMID: 38841819 PMC: 11154816. DOI: 10.1002/brb3.3548.


Prognostic relevance of MRI in early relapsing multiple sclerosis: ready to guide treatment decision making?.

Hoffmann O, Gold R, Meuth S, Linker R, Skripuletz T, Wiendl H Ther Adv Neurol Disord. 2024; 17:17562864241229325.

PMID: 38332854 PMC: 10851744. DOI: 10.1177/17562864241229325.


Bibliometric analysis of myelin imaging studies of patients with multiple sclerosis (2000-2022).

Chen X, Zhang J, Shen L, Chen Y, Yang J, Tang W Quant Imaging Med Surg. 2024; 14(1):837-851.

PMID: 38223029 PMC: 10784065. DOI: 10.21037/qims-23-1157.